Literature DB >> 7838837

Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues.

J A Holden1, G W Snow, S L Perkins, C J Jolles, C R Kjeldsberg.   

Abstract

DNA topoisomerase II is the molecular target of several clinically useful chemotherapeutic drugs. The sensitivity of cells to drugs that target topoisomerase II is dependent on the cellular content of this enzyme. Drug-sensitive cells have elevated amounts of type II topoisomerase. To determine relative amounts of enzyme in malignant neoplasms, we developed an in situ immunohistochemical stain for topoisomerase II. The stain uses either polyclonal or monoclonal antibodies produced against the alpha isoform of the enzyme. Staining can be done on both frozen and formalin-fixed, paraffin-embedded tissues. By using this immunostain, we found marked differences in enzyme content in several human malignancies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7838837

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

1.  Immunohistochemical localization of DNA topoisomerase II in human gastric disorders.

Authors:  J A Holden
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

2.  Organ Specific Tumor Markers: What's New?

Authors:  Kannan Vaidyanathan; D M Vasudevan
Journal:  Indian J Clin Biochem       Date:  2011-11-08

3.  Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.

Authors:  T A Järvinen; J Kononen; M Pelto-Huikko; J Isola
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

4.  DNA Topoisomerase II-alpha as a marker of cell proliferation in endocrine and other neoplasms.

Authors:  J A Holden
Journal:  Endocr Pathol       Date:  1999-06       Impact factor: 3.943

5.  The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.

Authors:  H Turley; M Comley; S Houlbrook; N Nozaki; A Kikuchi; I D Hickson; K Gatter; A L Harris
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.